Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Benefit of allograft in persistent mutations in NK-AML

ABSTRACT: Allogeneic transplant can abrogate the risk of relapse in the patients of first remission acute myeloid leukemia with detectable measurable residual disease by next-generation sequencing

PROVIDER: PRJEB32367 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	ERR3301040.fastq.gz	Fastqsanger.gz
	ERR3301040_1.fastq.gz	Fastqsanger.gz
	ERR3301040_2.fastq.gz	Fastqsanger.gz
	ERR3301050.fastq.gz	Fastqsanger.gz
	ERR3301050_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 834

Similar Datasets

Project description:Measurable Residual IDH2 before Allogeneic Transplant for Acute Myeloid Leukemia

| PRJNA1051602 | ENA

Project description:Measurable Residual IDH1 before Allogeneic Transplant for Acute Myeloid Leukemia

| PRJNA997373 | ENA

Project description:Measurable Residual Mutated NPM1 before Allogeneic Transplant for Acute Myeloid Leukemia

| PRJNA1140149 | ENA

Project description:Measurable Residual FLT3-ITD before Allogeneic Transplant for Acute Myeloid Leukemia

| PRJNA1021545 | ENA

scRNAseq of bone marrow (BM) T cells and hematopoietic stem and progenitor cells (HSPCs) of acute myeloid leukemia patients post allogeneic stem cell transplantation (alloSCT).

Project description:Gene expression profile at single cell level of bone marrow (BM) T cells and hematopoietic stem and progenitor cells (HSPCs) of acute myeloid leukemia patients post allogeneic stem cell transplantation (alloSCT) of patients in complete remission (CR) and relapse (REL).

2024-01-11 | GSE216187 | GEO

Molecular Characterization of Chemoresistant Cell Populations Improves Risk Stratification and Therapy Response Prediction in Pediatric AML [pAML PDX scRNA-seq]

Project description:Most pediatric acute myeloid leukemia (pAML) patients achieve complete remission after chemotherapy. However, relapse remains common, and nearly 40% ultimately die of the disease. Prognosis is guided by cytogenetic biomarkers and measurable residual disease (MRD) after one chemotherapy cycle, at which point the highest-risk patients are referred to targeted experimental therapies and stem cell transplantation (SCT). Because these therapies are most effective before relapse, accurate early risk prediction is essential for improving outcomes. To address help this need, we analyzed paired diagnosis–relapse samples from 33 pAML patients at single-cell resolution and identified chemoresistant pAML populations whose abundance at diagnosis significantly improved risk prediction. Incorporation of these populations into a risk model uncovered a previously unrecognized subgroup—representing 20% of pAML cases—with event-free survival (EFS) below 40%, accounting for half of the deaths among patients that were not prescribed SCT after a cycle of chemotherapy. Furthermore, molecular characterization of these chemoresistant populations revealed therapeutic targets and targeted interventions relevant to most high-risk patients, paving the way for more effective treatments for high risk pAML patients.

2025-11-26 | GSE271136 | GEO

Molecular Characterization of Chemoresistant Cell Populations Improves Risk Stratification and Therapy Response Prediction in Pediatric AML [pAML PDX Bulk RNA-seq]

2025-11-26 | GSE271134 | GEO

Molecular Characterization of Chemoresistant Cell Populations Improves Risk Stratification and Therapy Response Prediction in Pediatric AML [Treatment_Study_RNA-seq]

2025-11-26 | GSE308825 | GEO

Molecular Characterization of Chemoresistant Cell Populations Improves Risk Stratification and Therapy Response Prediction in Pediatric AML [pAML Patients scRNA-seq]

2025-11-26 | GSE270894 | GEO

Molecular Characterization of Chemoresistant Cell Populations Improves Risk Stratification and Therapy Response Prediction in Pediatric AML [pAML Patients Bulk RNA-seq]

2025-11-26 | GSE270892 | GEO